Cost-Effectiveness of Alternatives to Allogeneic Blood Transfusion; Reviewing the Available Evidence
Major progress has been made during the last decade in the safety of allogeneic blood products. Donor deferral and extended testing for viruses and bacteria substantially reduced risks associated with blood transfusion. The window period of detection is almost closed and any remaining pathogen might in future be eliminated by pathogen inactivation. However, the small risk of complications after blood transfusion still remains a major concern to the general public and health policy makers The perception of these risks and potential judicial consequences cause decision makers to favour implementation of procedures to further improve blood transfusion safety . Besides improving safety of allogeinic blood products itself, risk reduction can be achieved by limiting the number of allogeinic transfusions transfused to the recipient. These conservation strategies comprise autologous transfusion, acute normovolemic hemodilution, use of blood growth factors (erythropoietin), peri-operative cell salvage, artificial blood and development of guidelines for minimal use of blood transfusion [2–4] The utilisation of conservation technologies varies between and within countries . From a pharmaco-economic point of view it is relevant to investigate whether monetary benefits of averted transfusion complications by conservation techniques surpass the costs, or, whether the marginal net costs justify the health gains achieved.
KeywordsRecombinant Human Erythropoietin Allogeneic Transfusion Autologous Transfusion Preoperative Autologous Blood Donation Acute Normovolemic Hemodilution
Unable to display preview. Download preview PDF.
- 2.Practice strategies for elective red blood cell transfusion. American College of Physicians. Ann Intern Med. 1992; 116: 403–06.Google Scholar
- 3.Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. Second of two parts-blood conservation. N Engl J Med 1999; 340: 5 2533.Google Scholar
- 5.Fergusson D, Blair A, Henry D, et al. Technologies to minimize blood transfusion in cardiac and orthopedic surgery. Results of a practice variation survey in nine countries. International Study of Peri-operative Transfusion (ISPOT) Investigators. Int J Technol Assess Health Care 1999; 15: 717–28.PubMedGoogle Scholar
- 7.Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 1997.Google Scholar
- 8.Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.Google Scholar
- 11.Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine. Pharmacoeconomics. 1997; 11: 159–68.PubMedCrossRefGoogle Scholar
- 17.Jefferson T, Demicheli V, Mugford M. Elementary Economic Evaluation in Health Care. London: BMJ Publishing Group, 1996.Google Scholar
- 22.Kilgore ML,.Pacifico AD. Shed mediastinal blood transfusion after cardiac operations: a cost-effectiveness analysis. Ann Thorac Surg. 1998; 65: 124–854.Google Scholar
- 46.Hoffer S, Berardino F, Smith J, Rubin S. Economic Values for Evaluation of FAA Investment and Regulatory Decisions. Washington, DC: Federal Aviation Administration, Office of Aviation Policy, Plans, and Management Analysis Publication FAA-APO-98–8, 1998.Google Scholar